Evidence map›Paper›PMID 36677874›Full record

ArticleMolecules (Basel, Switzerland)2023

The miRNA-185-5p/STIM1 Axis Regulates the Invasiveness of Nasopharyngeal Carcinoma Cell Lines by Modulating EGFR Activation-Stimulated Switch from E- to N-Cadherin.

Yue Luo, Jiaxiang Ye, Yayan Deng, Yujuan Huang, Xue Liu, Qian He, Yong Chen, Qiuyun Li, Yan Lin, Rong Liang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yue LuoDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Jiaxiang YeDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yayan DengDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yujuan HuangDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Xue LiuDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Qian HeInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
Yong ChenDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Qiuyun LiDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yan LinDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.ORCID 0000-0001-8034-5946
Rong LiangDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yongqiang LiDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Jiazhang WeiDepartment of Otolaryngology & Head and Neck, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China.ORCID 0000-0001-8611-3118
Jinyan ZhangDepartment of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.ORCID 0000-0002-9874-2744
Guangxi Medical University · CNThe People's Hospital of Guangxi Zhuang Autonomous Region · CNTsinghua–Berkeley Shenzhen Institute · CN

Funding

Guangxi Natural Science Foundation 2020GXNSFBA297024 and 2020GXNSFBA297059National Natural Science Foundation of China 82073004, 81602390 and 82002859Open Research Project of Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education/Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor GKE-KF202206
6 · The paper itself

Abstract

Distant metastasis remains the primary cause of treatment failure and suggests a poor prognosis in nasopharyngeal carcinoma (NPC). Epithelial-mesenchymal transition (EMT) is a critical cellular process for initiating a tumor invasion and remote metastasis. Our previous study showed that the blockage of the stromal interaction molecule 1 (STIM1)-mediated Ca

Indexed as

Epstein-Barr Virus InfectionsMicroRNAsNasopharyngeal NeoplasmsAnimalsCadherinsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionErbB ReceptorsFollow-Up StudiesGene Expression Regulation, NeoplasticHerpesvirus 4, HumanHumansMiceNasopharyngeal CarcinomaCadherinsErbB ReceptorsMicroRNAsMIRN185 microRNA, humanNeoplasm ProteinsSTIM1 protein, humanStromal Interaction Molecule 1epithelial-mesenchymal transitionmiRNA-185-5pnasopharyngeal carcinomaSTIM1tumor invasion

Identifiers

PMID36677874
PMCPMC9864293
OpenAlexW4315864749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.